Abstract
Spinal cord injury (SCI) induces dynamic changes of the blood-spinal cord barrier and even the more distant blood-brain barrier. Besides an immediate increase of paracellular permeability resulting from the direct impact of the injury, the transport systems for selective cytokines undergo regulatory changes. Since many of the transported molecules play essential roles in neuroregeneration, we propose that this altered peripheral tissue / CNS interaction benefits remodeling of the spinal cord and functional recovery after SCI. This review examines the transport of cytokines and neurotrophic factors into the spinal cord, emphasizing the upregulation of two cytokines – tumor necrosis factor α (TNF) and leukemia inhibitory factor (LIF) - during the course of SCI. The increased transport of TNF and LIF after SCI remains saturable and does not coincide with generalized BBB disruption, highlighting a pivotal regulatory role for the bloodspinal cord barrier.
Keywords: Spinal cord injury, blood-brain barrier, cytokines, neurotrophins, TNF, LIF
Current Pharmaceutical Design
Title: Cytokine Transport Across the Injured Blood-Spinal Cord Barrier
Volume: 14 Issue: 16
Author(s): Weihong Pan and Abba J. Kastin
Affiliation:
Keywords: Spinal cord injury, blood-brain barrier, cytokines, neurotrophins, TNF, LIF
Abstract: Spinal cord injury (SCI) induces dynamic changes of the blood-spinal cord barrier and even the more distant blood-brain barrier. Besides an immediate increase of paracellular permeability resulting from the direct impact of the injury, the transport systems for selective cytokines undergo regulatory changes. Since many of the transported molecules play essential roles in neuroregeneration, we propose that this altered peripheral tissue / CNS interaction benefits remodeling of the spinal cord and functional recovery after SCI. This review examines the transport of cytokines and neurotrophic factors into the spinal cord, emphasizing the upregulation of two cytokines – tumor necrosis factor α (TNF) and leukemia inhibitory factor (LIF) - during the course of SCI. The increased transport of TNF and LIF after SCI remains saturable and does not coincide with generalized BBB disruption, highlighting a pivotal regulatory role for the bloodspinal cord barrier.
Export Options
About this article
Cite this article as:
Pan Weihong and Kastin J. Abba, Cytokine Transport Across the Injured Blood-Spinal Cord Barrier, Current Pharmaceutical Design 2008; 14 (16) . https://dx.doi.org/10.2174/138161208784705450
DOI https://dx.doi.org/10.2174/138161208784705450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity?
Current Aging Science Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Forensic Toxicology and Pharmacogenomics: Hype or Hope For Higher Standards in Forensic Medicine?
Current Pharmacogenomics and Personalized Medicine Possible Role of BDNF-Induced Microglial Intracellular Ca<sup>2+</sup> Elevation in the Pathophysiology of Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System
Current Neuropharmacology Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology
Current Neuropharmacology Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research